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The current therapy for glioblastoma multiforme involves total surgical resection followed by combination of radiation therapy
and temozolomide. Unfortunately, the eﬃcacy for such current therapy is limited, and newer approaches are sorely needed to treat
this deadly disease. We have recently described the isolation of bacterial proteins and peptides with anticancer activity. In phase
I human clinical trials, one such peptide, p28, derived from a bacterial protein azurin, showed partial and complete regression
of tumors in several patients among 15 advanced-stage cancer patients with refractory metastatic tumors where the tumors
were no longer responsive to current conventional drugs. An azurin-like protein called Laz derived from Neisseria meningitides
demonstrates eﬃcient entry and high cytotoxicity towards glioblastoma cells. Laz diﬀers from azurin in having an additional 39-
amino-acid peptide called an H.8 epitope, which allows entry and high cytotoxicity towards glioblastoma cells. Since p28 has
been shown to have very little toxicity and high anti-tumor activity in advanced-stage cancer patients, it will be worthwhile to
explore the use of H.8-p28, H.8-azurin, and Laz in toxicity studies and glioblastoma therapy in preclinical and human clinical
trials.
1. The Blood-Brain Barrier:A Major
Barrier to Glioblastoma Therapy
The brain is a protected organ and therefore limits the num-
ber of compounds that can enter it from peripheral circu-
lating blood. Thus only selected compounds such as glucose,
alcohol, nicotine, and others can enter the brain to help
nourish it or aﬀect it in other ways, but many other blood
components cannot enter the brain. This physical barrier,
termed the blood-brain barrier (BBB), is characterized by
monolayers of endothelial cells that are tightly packed to
prevent leakage of brain components or entry of nonpermis-
sive substances [1]. This entry is usually conﬁned to small
molecules of about 500 to 600 daltons (Da) although delta
sleep-inducing peptide or enkephalin analogs of higher mo-
lecular weights are also known to cross the BBB in sufﬁcient
amounts to aﬀect brain function. To complement this BBB,
there are also eﬄux proteins such as the P-glycoprotein that
can pump out many compounds from the brain vasculature,
adding to the restrictive entry to the brain.
The presence of the BBB, and the eﬃcient eﬄux mecha-
nism, has signiﬁcantly limited the number of drugs that can
enter the brain to treat brain pathologies, including brain
tumors.Transmembranediﬀusion,usuallybysmalllipophil-
ic molecules, has been the major route to designing drugs
that can enter the brain in amounts suﬃcient to provide ef-
fective treatment, although such molecules can be targets of
P-glycoprotein eﬄux [2]. Since most of the compounds that
can penetrate the BBB either employ various transporters or
even transmembrane diﬀusion, current drugs are designed
with the aim to use such mechanisms, as well as to interfere
with the eﬄux mechanism of the P-glycoproteins.2 ISRN Neurology
2.DesigningDrugstoCrossthe BBB
The entry limitations to the brain of most drugs intended for
the treatment of brain pathologies have triggered a ﬂurry of
activities to design drugs, lipophilic compounds with polar
groups, for example, that can cross the BBB to enter the
brain parenchyma by disrupting the tight junctions of the
endothelial cells of the brain capillaries. One approach uses
convection-enhanced delivery of the drugs through insertion
of selected catheters containing drugs that penetrate the
interstitial space to enter the brain parenchyma. Another de-
velopment involves the use of recombinant adeno-associated
virus expressing neurotrophic factors [3]. Physical disrup-
tion of the BBB can also be achieved through high localized
osmolarity in the intracarotid administration of hypertonic
mannitol solution followed by appropriate drugs [4]. The
most active area of neuroactive drug development involves
the use of transporters present on the capillaries of the neu-
rons that normally transport essential nutrients to the brain
through transcytosis. Such receptors, for example, insulin
receptor, transferrin receptor, low-density lipoprotein (LDL)
receptor, and so forth, can then endocytose any drug or
foreign protein conjugated to it, from the luminal side to
the abluminal side of the brain capillary endothelium [5] in-
cluding the use of receptors for LDL (LRP) which are often
overexpressed in tumors such as glioblastomas [6]. Targeted
delivery of proteins, such as lysosomal enzymes or green
ﬂuorescent protein, to the neurons and astrocytes through
use of lentivirus vector system and LRP-binding domain of
apolipoprotein B fused to the respective protein, has shown
great promise in potential therapeutic applications for cen-
tralnervoussystem(CNS)disorders[7].Similarviralvectors
have been used for potential glioblastoma gene therapy
throughdeliveryofvariousgenesthatpromotecelldeath[8].
The transcytosis of a carrier protein through binding
with the ApoB LDL receptor binding domain of about 38
amino acids has prompted investigations to use a family of
peptides derived from proteins that utilize LRPs for crossing
the BBB to deliver therapeutic agents [9, 10]. An example of
such peptides would be Angiopeps, a family of 19 amino acid
long peptides that are eﬃcient in using LRP type 1 to enter
thebrain.OnesuchpeptideAngiopep-2hasbeenconjugated
with paclitaxel to give rise to ANG1005. The eﬃcient tran-
scytosis of ANG1005, as compared to paclitaxel alone, and
its anticancer activity in vivo, has been demonstrated by en-
hanced survival of mice with implanted tumor [10]. Phase I
human clinical data show encouraging eﬃcacy of ANG1005
against recurrent malignant gliomas, as reported so far [11].
OtherpeptidessuchasTAT,homeodomainofAntennapedia,
and SynB have also been used, conjugated to therapeutic
compounds and with or without exposure on the surface of
nanoparticles,forentryintotheneuronsacrosstheBBB[12].
3. CurrentTrends in Glioblastoma Therapy
Glioblastoma multiforme (GBM) is one of the most deadly
gliomas because of its high genetic diversity, a complex vas-
culature giving rise to intratumoral pressure and invasive-
ness,andthelackofaccessofmostdrugsbecauseofthepres-
ence of entry barriers including the BBB. The invasive nature
of GBM, allowing it to spread throughout the CNS, makes
the therapy all the more diﬃcult, and the prognosis remains
poor [13]. The current standard of care involves gross total
surgical resection followed by combination of radiotherapy
with temozolomide and the continued adjuvant temozolo-
mide therapy. The radiation therapy for GBM involves focal,
fractionated external beam therapy while current drugs are
alkylating agents such as temozolomide, often in combina-
tion with inhibitors of growth factors that promote tumor
growth such as inhibitor (erlotinib) of epidermal growth
factor (EGF) receptor [14]. Even with such combination
therapy, the survival beneﬁts have been minimal, demon-
strating a need for improved therapeutic intervention. To
overcome the drug entry problem, attempts are being made
to use devices that can directly deliver a drug to the tumor. A
drug- (carmustine-) impregnated wafer can be placed in the
cavity after tumor resection or other anticancer agents can
be used in drug-eluting catheters placed in the cavity after
resection. The failure of most agents that hit a single target,
including monoclonal antibodies such as Avastin that target
the vascular endothelial growth factor (VEGF) and other
antiangiogenic agents [15], eliciting quick drug resistance as
wellasgivingrisetosigniﬁcanttoxicity,clearlyrequiresanew
approach and a new conceptual framework for the treatment
of cancers in general and GBM in particular [16, 17].
4.BacterialProteinsand Peptidesin
PotentialGBMTherapy: Novel Approaches
and New Horizons
Asmentionedabove,onlyselectedmoleculessuchasglucose,
insulin, and ethanol can cross the BBB to reach the brain
parenchyma and many blood components cannot cross this
barrier, yet certain extracellular bacterial pathogens that
are basically normal inhabitants in the pharyngeal region
(Neisseria meningitides, Streptococcus pneumoniae,e t c . )o r
in the gastrointestinal tract (Escherichia coli strain K1) can
cross the BBB to cause disease without having to hide in
leukocytes for crossing the BBB [18–20]. Although the tran-
scytosisofsuchbacteriathroughhumanbrainmicrovascular
endothelial cells has been well established [21], very little
is known about how such a bacterium, N. meningitides,
for example, actually crosses the BBB to invade the brain
meninges. Certain bacterial components, the capsules, and
virulence factors such as factor H binding protein or iron
acquisition system, as well as pili such as type IV pili, have
been implicated in the successful adhesion, host signaling to
disrupttheBBB,andbindingtothemeninges[21].Nosingle
bacterial component has been shown to allow N. menin-
gitides for eﬃcient transcytosis to the brain meninges.
An important aspect of basic research is the unpre-
dictability of the direction it will take. Thus fundamental
basic research has contributed to many out-of-the-box ideas
and new approaches for drug development and therapeutic
intervention. Let us give an example. About 12 years ago,
we had no interest or expertise in cancer research, including
development of anticancer drugs. We were studying theISRN Neurology 3
mechanism of infection of a bacterium known as Pseudomo-
nas aeruginosa in the lungs of cystic ﬁbrosis (CF) patients.
Similar to the long-term nasopharyngeal colonization by
Neisseria meningitides, Streptococcus pneumonia, and others
mentioned earlier, chronic infections in the lungs of CF
patientsareknowntobecausedbyP. aeruginosa byforminga
bioﬁlm on the epithelial cells of the lung through production
of various polysaccharides. The slow-growing bioﬁlms take
up little nutrients and produce little toxic metabolites in the
host, but are rendered resistant to antibiotics and immune
attack and are hard to eradicate. Since P. aeruginosa is an
opportunisticpathogenthatnormallydoesnotinfecthealthy
people with normal immune function, and CF patients have
normal immunity, we were interested in knowing if the
infecting P. aeruginosa cells produce any new toxin in the
environment of the CF lung that might be cytotoxic for
the foot soldiers of the immune system such as neutrophils
and macrophages. We, therefore, tested the growth media
of a clinical isolate of P. aeruginosa from the sputum of
CF patients for cytotoxicity against J774 cells, which are
widely used as a cell line with macrophage activity. Indeed,
the growth medium showed the presence of high cytotoxic
activity against such J774 cells. Further fractionation of the
growth medium showed the presence of two proteins, azurin
and cytochrome c551, which retained the cytotoxic activity
against J774 cells. Azurin, in particular, showed strong cyto-
toxic activity, although azurin was believed at that time to
be involved in electron transport in P. aeruginosa as a redox
proteinwithcytochromec551asitselectrontransferpartner.
Highly encouraged by these initial observations that we
have found a new toxin against macrophages (and a new
hitherto unknown function for azurin), our group checked
the cytotoxic activity of puriﬁed azurin against primary
mouse macrophages isolated from the peritoneum. To our
utter surprise, azurin again demonstrated high cytotoxicity
in J774 cells but very little cytotoxicity for mouse primary
peritoneal macrophages. Repeated experiments showed the
same results. With a great deal of confusion and anguish, we
searched for the diﬀerence between J774 cells and normal
peritoneal macrophages, until it dawned to us that J774
macrophage cell line is derived from tumors, allowing them
to grow rapidly in cell culture and facilitating their use as
macrophages.
Does azurin demonstrate cytotoxicity against tumor cells
but not against normal cells like peritoneal macrophages?
Further experiments clearly demonstrated that azurin not
only had high cytotoxicity against human cancer cell lines
suchasmelanomaandbreastcancershowingverylittletoxic-
ity in normal cells, but also showed a great deal of promiscu-
ity in attacking and demonstrating high cytotoxicity against
viruses such as the AIDS virus HIV-1 or parasites such as
the malarial parasite Plasmodium falciparum or the toxo-
plasmosis-causing parasite Toxoplasma gondii [22, 23]. Such
promiscuityofazurinwasnotonlyconﬁnedtoitsanticancer,
antiviral; or antiparasitic activities, but extended to multiple
steps in cancer growth progression pathways that were
signiﬁcantly inhibited by azurin. For example, azurin enters
preferentially to cancer cells than to normal cells and inhibits
the cancer cell growth by interfering in multiple steps in its
growthsuchasreceptortyrosine-kinase-mediatedcellsignal-
ing, EGF-EGFR-mediated angiogenesis and inducing apop-
tosis through stabilization of tumor suppressor p53 by pre-
venting its ubiquitination. No rationally designed drug can
match this kind of mode of anticancer action (interference
in multiple steps) of azurin, including its entry speciﬁcity
in cancer cells [23]. It should be emphasized that these were
the pathways that we studied with respect to cancer growth
inhibition by azurin. It is likely that azurin may impact many
otherpathwaysincancercellgrowththatonlyanintelligently
designed weapon produced by bacteria with 3 billion years
of evolutionary wisdom can target to keep cancers in check.
Because such a bacterial protein weapon that forms com-
plexes with many human/eukaryotic proteins important for
disease progression must work in an animal or human cel-
lular environment where the bacteria reside, it is interesting
to note that azurin structurally resembles immunoglobulins,
making it mostly a nonimmunogenic protein, so that it
would not be eliminated by the body’s immune system when
released from bacteria to attack cancer cells.
4.1. Azurin-Like Protein, Neisseria meningitides, and Glioblas-
toma. Azurin, 128 amino acid long and about 14kDa, is not
only produced by P. aeruginosa b u tb ym a n yo t h e rb a c t e r i a .
Azurins are found in some members of the gamma and beta
subdivisions of the Proteobacteria but absent from the other
bacterial phyla and the Eukarya (Figure 1). They are mem-
bers of the cupredoxin superfamily represented by water-
soluble small copper-containing proteins (10–20kDa) in-
volved in electron transfer reactions [24, 25]. Although the
sequence homology between the azurins varies between 50
and 90%, the structural homology between these molecules
is highly conserved. All azurins have a characteristic single-
domain signature that consists of a compact structurally
rigidβ-sandwichcore(immunoglobulinfold)formedbytwo
main β-sheets made up of seven or more parallel and anti-
parallel strands (Greek key β-barrel structure). In addition,
azurins possess an essentially neutral hydrophobic patch sur-
rounding the copper site [25].
Of interest is the presence of an azurin-like protein,
termedLaz,uniquelyfoundinNeisseria speciesincludingthe
meningococcus and the gonococcus (Figure 1). Unlike other
bacterial azurins where azurin is periplasmic, Neisserial
azurinissurfaceexposedandharborsanadditional39amino
acid moiety in its N-terminal called an H.8 epitope [27, 28].
Beyond this 39 amino acid N-terminal region in Laz is a 127-
amino-acid azurin domain at the C-terminal that is highly
homologous to the P. aeruginosa azurin (Figure 2). The size
of the Laz protein can be somewhat variable among the
Neisseria species but generally contains imperfect AAEAP
pentameric repeat motifs in the H.8 epitope, no aromatic
amino acids, and a lipid-modiﬁed N-terminal cysteine res-
idue (Figure 2)[ 28].
Azurin is believed to be a weapon produced by some
pathogenic bacteria such as P. aeruginosa or N. meningitides,
which reside in the human body and where azurin is released
in response to invasion by internal or external invaders such
as cancers, viruses, and parasites, which can cause harm4 ISRN Neurology
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Figure 1: Occurrence of azurin-like proteins across a phylogenetic tree. By homology searches, azurin orthologous were found in a variety
of bacterial species members of the gamma- and betaproteobacteria but absent from the other bacterial phyla and the Eukarya. Black and
white boxes indicate presence and absence of azurin, respectively. The box with vertical bars indicates the existence of an azurin-like protein
(termedLaz)inNeisseriaspecies.Shownontherightaretheschematicrepresentationsoftheconservedcoredomainpresentedinazurin-like
proteins (COX2 superfamily). The phylogenetic tree was drawn using STRING [26]. SP: signal peptide.
to the host and causing loss of sanctuary for the bacteria
[22, 23]. It is thus interesting to note that Neisseria such as
N. meningitides chose to put an additional armor, such as
the H.8 epitope, in its weapon azurin, giving rise to Laz.
Why does N. meningitides need this additional armor that
P. aeruginosa does not? A look at the residency pattern of
these two opportunistic pathogens demonstrates that while
P. aeruginosa can seldom cross the BBB to invade the brain
meninges to reside there, N. meningitides is known to do so,
as mentioned earlier. While resident in the brain meninges,
N. meningitides may feel threatened to lose its habitat if a
brain tumor, such as a glioblastoma, crops up in the vicinity.
SimilartotheBBB,theglioblastomamayhavetightjunctions
that may prevent azurin to enter the tumor to kill it and
azurinneedsanadditionalcomponenttohelpitdisruptsuch
an entry barrier. Additionally, instead of being periplasmic
as for all other azurins, surface exposure of Laz allows this
armor(H.8epitope)tohelpinthetranscytosisofthebacteria
to cross the BBB as well.
Does the presence of the H.8 epitope in azurin, that is,
Laz, allow facilitated disruption of any entry barrier to the
glioblastomas or even help in crossing the BBB? Even more
pertinent is the question: does the bacterial weapon azurin
work in the human environment to attack tumors and cause
their regression?
BecauseazurinandLazarebacterialproteins,forpreclin-
ical or human clinical trials, they face stringent regulation
and may have toxic cellular contaminants. On the other
hand, a peptide derived from azurin or Laz, which can be
chemically synthesized as a drug, has entry speciﬁcity in can-
cer cells and demonstrated anticancer activity and therefore
can be tested clinically for toxicity and eﬃcacy in humans.
Such a peptide is p28, a 28-amino-acid peptide derived from
azurin(azurin50–77)withentryspeciﬁcityincancercells,as
well as with anticancer activity [31]. Eleven US patents have
been issued on these candidate drugs since 2006 (Table 1)
coveringtheuseofasingleproteinorpeptidedrugformulti-
ple diverse diseases. A start-up company, CDG Therapeutics
Inc. (CDGTI), sponsored both preclinical and human phase
I clinical trials with p28 as an anticancer agent. In preclinical
trials, p28 showed no toxicity or immunogenicity in animals,
including monkeys, which prompted a phase I humanISRN Neurology 5
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Figure 2: (a) A multiple amino acid alignment of 9 representative bacterial azurins and 3 azurin-like proteins (Laz) from neisserial species.
Identical residues (), conservative amino acid substitutions (:), and semiconservative amino acid substitutions (.) are shown below the
aligned sequences. Laz and azurins that were used included are the following: Laz from N. gonorrhoeae FA 1090 (YP 208090.1); H.8 outer-
membranelipoproteinfromN.meningitidisWUE2594(CBY91147.1);azurinfromN.lactamicaATCC23970(ZP 05986830.1);azurinfrom
Bordetella pertussis Tohama I (NP 879636.1); azurin from Achromobacter xylosoxidans AXX-A (EGP47536.1); azurin from P. aeruginosa
PAO1 (NP 253609.1); azurin from Pseudomonas syringae pv. glycinea str. race 4 (EGH06424.1); azurin from Achromobacter xylosoxidans
(BAA33677.1); azurin from Burkholderia cepacia (AAP03090.1); azurin from Pseudomonas mendocina ymp (YP 001186158.1); azurin from
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was used to generate this multiple sequence alignment. (b) A phylogenetic tree calculated from the alignment represented above in (a).
Clustal X with neighbour-joining method [30] was used to construct the tree.
clinical trial in Chicago. This trial comprised 15 advanced-
stage cancer patients with metastatic, refractory solid tumors
(7 melanoma, 4 colon, 2 sarcoma, 1 pancreatic, and 1 pros-
tate) and with an average life expectancy of less than 6
months and where the tumors were no longer responding
to conventional drugs. When chemically synthesized p28
was given as an intravenous bolus in 5 escalating doses for
4 weeks, followed by a 2-week break before the next higher
dose, several patients showed partial regression of their
tumors with 2 patients (1 melanoma, 1 sarcoma) showing
complete regression. Very little toxicity was seen even with
the highest concentration of p28, and 1 patient, out of 6
surviving patients, has been living disease-free for over 80
weeks ([32]a n dhttp://www.cdgti.com/).
The fact that out of 15 patients where the tumors
were refractory to all conventional drugs, 2 patients showed
complete regression of their tumors with enhanced life
expectancy raises important questions not only about the
unique mode of action of p28, and therefore azurin, but also
about the genetic traits, either in the tumor genome or in the
patientgenome,thatmakethesetumorshighlysusceptibleto
p28. The complete tumor regression may also be due to the
right concentrations of p28 and the right length of time of
treatment.Itshouldbenotedthatp28isonlyapartofazurin,
and there are other domains in azurin, p26, for example,
that demonstrate anticancer activity through inhibition of
receptor tyrosine kinases such as EphB2 [33], or others. Thus
azurinwilllikely beamorepotent anticanceragentthanp28,
provided its lack of toxicity and immunogenicity in humans
can be demonstrated.
The presence of an additional H.8 epitope in neisserial
azurin (Laz) begs the question if indeed the H.8 epitope
facilitates the anticancer weapon azurin to cross any entry
barrier to glioblastomas, and given the surface exposure of6 ISRN Neurology
Table 1: List of issued US patents on protein drugs azurin and Laz.
Title Inventors Patent number Date of issuance
Cytotoxic factors for modulating cell death Chakrabarty AM, Das Gupta TK, Punj V,
Zaborina O 7,084,105 August 1, 2006
Compositions and methods for treating
HIV infection with cupredoxins and
cytochrome c
Chakrabarty AM, Das Gupta TK, Yamada
T, Chaudhari A, Fialho A, Hong CS 7,301,010 November 27, 2007
Compositions and methods for treating
malaria with cupredoxin and cytochrome
Chakrabarty AM, Das Gupta TK, Yamada
T, Chaudhari A, Fialho A, Hong CS 7,338,766 March 04, 2008
Compositions and methods for treating
conditions related to ephrin signaling with
cupredoxins
Chakrabarty AM, Das Gupta T, Yamada T,
Chaudhari A, Fialho A, Zhu Y 7,381,701 June 03, 2008
Cytotoxic factors for modulating cell death Chakrabarty AM, Das Gupta TK, Punj V,
Zaborina O, Hiraoka Y, Yamada T 7,491,394 February 17, 2009
Compositions and methods for treating HIV
infection with cupredoxin and cytochrome c
Chakrabarty AM, Das Gupta, T, Yamada,
T, Chaudhari A, Fialho A, Hong CS 7,511,117 March 31, 2009
Compositions and methods to control
angiogenesis with cupredoxins
Mehta RR, Taylor BN, Yamada T, Beattie
CW, Das Gupta TK, Chakrabarty AM 7,556,810 July 07, 2009
Compositions and methods to prevent
cancer with cupredoxins Das Gupta TK, Chakrabarty AM 7,618,939 November 17, 2009
Cupredoxin derived transport agents and
methods of use thereof
Chakrabarty AM, Das Gupta T, Yamada T,
Fialho A 7,691,383 April 06, 2010
Compositions and methods for treating
malaria with cupredoxin and cytochrome
Chakrabarty AM, Das Gupta T, Yamada T,
Chaudhari A, Fialho A, Hong CS 7,740,857 June 22, 2010
Transport agents for crossing the
blood-brain barrier and into brain cancer
cells, and methods of use thereof
Hong CS, Yamada T, Fialho A, Das Gupta
TK, Chakrabarty AM 7,807,183 October 5, 2010
Laz in N. meningitides, whether the H.8 epitope might even
be involved in facilitated BBB crossing that N. meningitides
must accomplish to invade the brain meninges. We have,
therefore, tested the entry speciﬁcity of P. aeruginosa azurin
(Paz), neisserial azurin (Laz), and an additional construct
H.8-azurin where the H.8 epitope from Laz was cloned in
the N-terminal part of Paz to produce the chimeric protein
H.8-azurin (Figure 3). The entry speciﬁcity and cytotoxicity
of these three proteins were then tested in human breast
cancer MCF-7 and glioblastoma LN-229 cells [28, 34]. As
shown in Figure 3 (top row), when azurin was conjugated
to a ﬂuorescent red dye Alexa Fluor 568 and looked for entry
in breast cancer MCF-7 as well as the glioblastoma LN-229
cells, it entered the MCF-7 cells very eﬃciently but the entry
to LN-229 cells was limited and ineﬃcient. In contrast, Laz,
with the H.8 epitope in its N-terminal, entered both MCF-
7 and LN-229 cells eﬃciently (Figure 3, middle row). Most
interestingly, when the H.8 epitope was introduced in the N-
terminal part of P. aeruginosa azurin, this chimeric protein
could enter both MCF-7 and LN-229 cells very eﬃciently,
similar to Laz but very unlike P. aeruginosa azurin (Figure 3,
bottom row). This clearly suggests that the H.8 epitope
significantly facilitates the entry of azurin to glioblastoma
cells.
How may the H.8 peptide facilitate such entry of azurin
in glioblastoma cells? Does it disrupt any entry barrier, per-
haps the tight junctions in the LN-229 cells? To address
such questions, we used chemically synthesized 39-amino-
acid H.8 peptide by itself, labeled with Alexa Fluor 568, for
its entry or unlabeled H.8 peptide for cytotoxicity in LN-229
and MCF-7 cells. The H.8 peptide by itself did not show any
entry or cytotoxicity in these cancer cells [28]. While azurin
by itself showed much less cytotoxicity in glioblastoma LN-
229 cells as compared to H.8-azurin and Laz (Figure 3,
cytotoxicity assays), when the chemically synthesized H.8
epitope peptide was present along with azurin as a mixture
(as compared to H.8-azurin where it was fused to azurin),
the mixture showed a much higher entry level of azurin,
and corresponding cytotoxicity, than azurin alone, clearly
demonstrating a role of the H.8 epitope in facilitating the
entry of azurin, or perhaps any other drug, to the glioblas-
toma cells [28].
Does the H.8 epitope promote the crossing of the BBB
as well? Azurin, H.8-azurin, and Laz were each ﬂuorescently
labeled with green ﬂuorescing IR dye 800 CW (LI-COR
Biotechnology, Lincoln, Nebraska) and 500μgo fe a c hw a s
injected intraperitoneally in live nude mice to look for their
transport to the brain. After 24 hours, the mice were sac-
riﬁced, the brains isolated, and the ﬂuorescent images were
measured with a LI-COR Odyssey Infrared Imaging System.
Very little ﬂuorescent azurin was detected in the brain,
whilebothﬂuorescentLaz,andparticularlyH.8-azurin,were
detectedatamuchhigherlevel(Figure 4),suggestingthatthe
presence of the H.8 epitope in azurin allowed this protein to
more eﬃciently cross the BBB to reach the brain than free
azurin [34].ISRN Neurology 7
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Figure 3: Left row: structural depiction of azurin, Laz (with the H.8 epitope in the N-terminal), and azurin with the cloned H.8 epitope
in its N-terminal. The area corresponding to the p28 peptide region is marked. Middle row: the entry of ﬂuorescently labeled azurin, Laz,
and H.8-azurin in breast cancer MCF-7 and glioblastoma LN-229 cells is shown. The red color reﬂects the Alexa-Fluor-568-conjugated
protein while the blue color represents the nucleus stained with DAPI. Right row: cytotoxicity of azurin, H.8-azurin, and Laz at 3 diﬀerent
concentrations towards LN-229 glioblastoma cells. The detailed methodologies have been described by [28].
5. Concluding Remarks
Surgery, radiation, and chemotherapy, the main approaches
to cancer therapy, do not work very well for glioblastoma
mainly for two reasons. Firstly, few chemotherapeutic drugs
can cross the BBB to reach the brain tumor in signiﬁcant
amounts for therapeutic purposes. A second problem in-
volves the high invasive nature of glioblastomas within the
central nervous system, greatly accelerating the chances for
relapse of the tumor. Thus any approach to glioblastoma
therapy must take into consideration not only the need for
complete tumor removal but also to reduce the possibility of
a relapse. It is interesting to point out that azurin has both
these properties. Azurin and p28 not only have anticancer
activity, interfering in multiple steps in cancer growth, but
also have cancer preventive properties, as determined by
inhibition of the oncogenic transformation of normal mouse
mammary cells to develop precancerous lesions in presence
of a potent carcinogen, 7,12-dimethyl-benz-anthracene [35].
The lack of toxicity of p28 in advanced-state cancer patients
has been demonstrated, as stated earlier. It is likely that
azurin, and hopefully Laz and H.8-azurin, will prove to be
nontoxicinhuman.Althoughtheirstabilityinserumislikely
going to be low, not only Laz or H.8-azurin can potentially
be eﬀective in postsurgical glioblastoma patients but also
perhaps these two proteins, and azurin and p28, can be ef-
fectiveinpreventingtheemergenceoftumorsinwomenwith
BRCA1/BRCA2 mutations. These mutations in the human
genome are known to make women (and to some extent
men) susceptible to breast and ovarian (and in case of men,
prostate) cancers. Once the genetic tests show the presence
of such mutations in a person with a family history of breast
cancer, that person has very little recourse other than surgery
even before the cancer appears. As technologies advance, and
solid state peptide synthesis extends to peptides of 100 to
150 amino acid length as it is now, it might be possible to
chemically synthesize azurin, H.8-azurin, or Laz as potential
drugs, similar to p28. The only other issue would be to con-
jugate them with compounds that would make them suitable
tobetakenorallyratherthanthroughintravenousinjections.
That will make p28, azurin, H.8-azurin or Laz “a pill a day
to keep cancers away.” Alternatively, given azurin’s structural
similarity to immunoglobulins, lack of its immunogenicity,
and possible lack of toxicity, it should be possible to use
gene therapy [7, 8] to allow its expression from the human
genome, thus guarding the human body from invasion not
onlybycancers,butalsobyvirusessuchasHIV-1orparasites
such as the malarial parasite [23].8 ISRN Neurology
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Figure 4: Odyssey scanning of brains from mice previously injected peritoneally with green ﬂuorescent IR-dye-conjugated Laz, H.8 azurin,
and azurin (from P. aeruginosa). Individual mice were injected with individual ﬂuorescent protein, and the mice were sacriﬁced after 24
hours to obtain the brains for Odyssey imaging.
Finally, the eﬃcacy of p28 in allowing complete regres-
sion of tumors in a melanoma and a sarcoma patient, where
the tumors were nonresponsive to conventional drugs, raises
some interesting questions. Apart from the question of the
genotypic characteristics of the tumor or patient genomes
as mentioned earlier, could it be due to the unique char-
acteristics of the bacterial protein/peptide drugs that work
through novel multiple pathways? It should be noted that
p28, and in fact azurin, are known to enter breast cancer
tumorsvery eﬃcientlyandallowsigniﬁcanttumorshrinkage
in vivo in nude mice (reviewed in [23]). Unfortunately, no
breast cancer patient was recruited for the phase I trial with
p28butsubsequentphaseIItrials,hopefullyrecruitingnewly
diagnosed breast and other cancer patients, should shed
considerable light on the scope of the eﬃcacy of p28 for
other cancers as well. The other important question is if
azurin (p28) is a unique potential bacterial protein (peptide)
anticancer drug or if other bacteria with long-term residence
in the human body may produce similar protein weapons
to defend their habitat (human body) from invaders like
cancers, thus enlarging our repertoire of bacterial anticancer
drugs. It is interesting to note that an Indian company,
Amrita Therapeutics (http://www.amritatherapeutics.com/),
has reported the isolation of a similar protein, ATP-01 (and a
chemically synthesized peptide AT-01 derived from ATP-01)
from other bacteria as well. Although completely diﬀerent
from azurin in amino acid sequence and other features, ATP-
01 shows structural similarity to the immunoglobulin fold of
azurin, a similar size (about 17kDa) and with anticancer and
anti-HIV/AIDS activity. The data in Figure 5 demonstrate
the anticancer activity of the peptide AT-01 derived from
the mycobacterial protein ATP-01. Although the cytotoxic
activity of AT-01 is lower in glioblastoma cell line U87
than for skin or liver cancer cell lines, it is comparable to
cisplatin at similar concentration, and perhaps this activity
can be enhanced by fusing AT-01 with the H.8 epitope.
Whether such bacterial protein/peptide drugs as azurin and
ATP-01 or their peptides p28 and AT-01 will prove to be
nontoxic and eﬀective in cancer patients will determine if
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Figure 5: Cytotoxicity eﬀect of AT-01 peptide and cisplatin at 1μM
on U87 human glioblastoma, A431 skin cancer, and HepG2 liver
cancer cell lines. Cancer cells (1 × 104) were seeded, and after 24
hours the cells were treated separately with 1μM concentration of
AT-01peptideandcisplatinasapositivecontrol.Theviabilityofthe
cells was estimated by using MTT assay on the basis of formazan
formed, which was detected spectrophotometrically by measuring
optical density at 595nm at 24 hours, and % cell cytotoxicity was
determined [28].
our next-generation anticancer drugs will be of microbial
origin, perhaps rivaling the antibiotic industry.
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